Literature DB >> 4538911

The second international reference preparation of erythropoietin, human, urinary, for bioassay.

L Annable, P M Cotes, M V Mussett.   

Abstract

A collaborative study of the second international Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay was carried out in 10 laboratories. Combined potency estimates obtained by comparison with the International Reference Preparation, indicate that ampoules of the second Preparation contain 10.0 IU (weighted mean potency) or, taking the unweighted mean potency, 9.8 IU, with fiducial limits (P=0.95) of 8.4-11.5 IU. The second Preparation could be used as a standard in estimating the potency of a preparation of sheep plasma erythropoietin (68/307) although, as with the International Reference Preparation, there was a tendency for the sheep plasma preparation to produce log-dose-log-response regression lines that were steeper than those produced by the second Preparation.In accelerated degradation studies of the second Preparation stored as the dry product in ampoules for up to 1 year, there was no consistent trend to indicate instability of the preparation.Following its establishment in 1971, the Second International Reference Preparation was allocated a potency of 10 IU/ampoule.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4538911      PMCID: PMC2480819     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  1 in total

1.  The international reference preparation of erythropoietin.

Authors:  P M Cotes; D R Bangham
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

  1 in total
  12 in total

1.  Serum erythropoietin level: relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow.

Authors:  W Jelkmann; G Wiedemann
Journal:  Klin Wochenschr       Date:  1990-04-17

2.  Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes : a population approach.

Authors:  A Gaudard; E Varlet-Marie; M Audran; R Gomeni; F Bressolle
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

3.  Evidence against a major role for Ca2+ in hypoxia-induced gene expression in human hepatoma cells (Hep3B).

Authors:  E Metzen; J Fandrey; W Jelkmann
Journal:  J Physiol       Date:  1999-06-15       Impact factor: 5.182

4.  The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.

Authors:  J D Jensen; L W Jensen; J K Madsen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Authors:  I C Macdougall; D E Roberts; G A Coles; J D Williams
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

6.  [Humoral factors in the regulation of cell proliferation in haematopoiesis. II. Erythropoiesis, megakaryopoiesis, multipotent stem cell (author's transl)].

Authors:  E Heidemann
Journal:  Klin Wochenschr       Date:  1980-11-03

7.  Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas.

Authors:  A J Gross; M Wolff; J Fandrey; W D Miersch; K P Dieckmann; W Jelkmann
Journal:  Clin Investig       Date:  1994-05

8.  Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures.

Authors:  M Wolff; W Jelkmann
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

9.  Photometric characteristics of haem proteins in erythropoietin-producing hepatoma cells (HepG2).

Authors:  A Görlach; G Holtermann; W Jelkmann; J T Hancock; S A Jones; O T Jones; H Acker
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

10.  The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

Authors:  J Brockmöller; J Köchling; W Weber; M Looby; I Roots; H H Neumayer
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.